Download Global Peptide Antibiotics Market and Clinical Pipeline Insight 2023 Report

“Global Peptide Antibiotics Market and Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.

Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US$ 40 Billion by 2023 from less than US$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have tremendous impact in revolutionizing the new era of antibiotics.

US dominate the global production and commercialization of peptide antibiotics followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics. Their dominance in the global antibiotics market is estimated to remain stable over the next years. However, developing nations like China and India are believed to contribute significantly to the overall growth of the antibiotics market in the near future with their incessant population and demand for antibiotics growing at an alarming rate annually. The success of peptide vaccines would greatly impact the global antibiotics scenario with the conventional antibiotics being replaced. However the rate at which this would happen is still uncertain.

FDA has approved vanomycin and bacitracin as peptide antibiotics, largely used for the treatment of bacterial infection. Recent innovations and advancement in the peptide antibiotics segment has further opened up opportunities in the oncology field with researchers trying to find antibiotics against carcinogenic bacterial infections. Increase in antibiotic resistance, emergence of large scale infections and new opportunities in the oncology segment have led to increased investment in the peptide antibiotics market which seems to be the best alternative healthcare researchers have .These have altogether been the major driving factors in the development of peptide antibiotics.

With the advancement in scientific knowledge and increased research globally, the peptide antibiotics segment is bound to rise. Collaborations between major pharmaceuticals giants fuelled by increased investment and support from various government and foundations have positively impacted the growth in the peptide vaccine market. It is evident that antibiotic resistance would severely impact the antibiotics market, thus the dire need for an alternative. This particular need can successfully be fulfilled by the emergence of peptide antibiotics which would rapidly become an alternative or the most possible solution in situations where the conventional antibiotics fail. Thus it could fairly be concluded that the peptide antibiotics are the new plethora of opportunities with the potential of generating immense revenue in the future.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-peptide-antibiotics-market-and-clinical-pipeline-insight-2023.php

1. Peptide Antibiotics - A New Era for Antibiotics
1.1 Introduction
1.2 Systemization of Peptide Antibiotics and Drugs
1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics
1.2.2 Ribosomal Synthesized Peptide Antibiotics

2. Mechanism and Production of Peptide Antibiotics
2.1 Approach of Peptide Antibiotics on Bacterial Surface
2.2 Creational Process of Peptide Antibiotics

3. Identification of Human Antimicrobial Peptides
3.1 Human Defensins
3.2 Human Cathelicidins
3.3 Antimicrobial Neuropeptides

4. Portrayal of Peptide Antibiotics in Cancer Treatment
4.1 Introduction
4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment

5. Categorization of Anticancer Peptides
5.1 Alpha-Helical Anticancer Peptides
5.2 Beta-Sheet Anticancer Peptides

6. Approved Peptide Antibiotics
6.1 Bacitracin
6.2 Viomycin

7. Market Analysis of Peptide Antibiotics
7.1 Introduction to Antibacterial Drug Market
7.2 Global Antimicrobial Peptide Market

8. Market Dynamics of Antimicrobial Peptides
8.1 Favorable Parameters
8.2 Challenges

9. Future Perspective of Peptide Antibiotics Market and Drug Development

10. Global Peptide Antibiotics Clinical Pipeline Overview
10.1 By Country
10.2 By Indication
10.3 By Mode of Action
10.4 By Formulation
10.5 By Delivery Route

11. Global Peptide Antibiotics Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration

12. Marketed Peptide Antibiotics Clinical and Patent Analysis
12.1 Telavancin (Arbelic and Vibativ)
12.2 Dalbavancin (Dalvance and Xydalba)
12.3 Daptomycin Intravenous (Cubicin)
12.4 Oritavancin (Nuvocid and ORBACTIV)
12.5 Teicoplanin (Targocid)
12.6 Vancomycin (Vancomycin hydrochloride)

13. Competitive Landscape
13.1 AMP Therapeutics
13.2 Eli Lilly
13.3 GlaxoSmithKline
13.4 Hospira
13.5 Kasten
13.6 Madam Therapeutics
13.7 Novartis
13.8 Pacgen Life Science Corporation
13.9 Pfizer
13.10 Phosphagenics
13.11 Savara Pharmaceuticals
13.12 Theravance
13.13 Vicuron Pharmaceuticals

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

KuicK Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.